Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally Bristol Myers SquibbFDA accepts Bristol Myers Squibb’s application for Sotyktu in psoriatic arthritis Investing.comFDA Review: Bristol Myers’ Sotyktu Could Become First TYK2 Inhibitor for Psoriatic Arthritis Stock Titan
